Immune Pharmaceuticals Inc (fka IMNPQ)

[Blue Sun]

GOOD NEWS ON THE WAY..
FORT LEE - Immune Pharmaceuticals, Inc.(OTCQB: IMNP) ('Immune' or the 'Company'), a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to bertilimumab for the treatment of bullous pemphigoid.

'I am truly grateful that the FDA has granted Fast Track designation to bertilimumab for the treatment of bullous pemphigoid. This important achievement follows the recent granting of Orphan Drug Designation in both the United States and Europe, which together demonstrate the regulatory affairs momentum our team has achieved,' commented Immune's Interim Chief Executive Officer, Tony Fiorino, MD, PhD. 'There is no doubt that bertilimumab development will benefit from the opportunity to have more frequent contact with the FDA, particularly now, as we move forward with a new manufacturing process and plan for a phase 2/3 pivotal study in bullous pemphigoid.. $IMNP